T2DM Diagnosis Confirmed
A1c ≥6.5%, FPG ≥126, or 2hr PG ≥200
All Pathways
Internal MedicineManagement
Type 2 Diabetes Management (ADA 2025)
Type 2 Diabetes Management (ADA 2025): T2DM Diagnosis Confirmed → Lifestyle Management (All Patients) → Assess CV/Renal Risk → ASCVD, HF, or CKD Present...
Pathway Overview
13 steps
Algorithm Steps
13 total
01Start 02Action Lifestyle Management (All Patients)
Foundation of diabetes care
- Medical nutrition therapy
- Weight management (if overweight/obese)
- Physical activity: 150+ min/week moderate
- Diabetes self-management education
- Smoking cessation
03Decision Assess CV/Renal Risk
Key determinant of agent selection
- Established ASCVD?
- Heart failure (HFrEF or HFpEF)?
- CKD (eGFR <60 or UACR >30)?
- High CV risk factors?
04Action ASCVD, HF, or CKD Present
Select agent with proven benefit
- GLP-1 RA with CV benefit (ASCVD)
- SGLT2i (HF or CKD preferred)
- Can use BOTH for additive benefit
- Add metformin if tolerated
05Action GLP-1 RA or SGLT2i Selection
For cardiorenal protection
- GLP-1 RA: semaglutide, dulaglutide, liraglutide
- SGLT2i: empagliflozin, dapagliflozin, canagliflozin
- HF: prefer SGLT2i
- ASCVD: either or both
06Decision Reassess A1c at 3 Months
Target individualized (usually <7%)
- <7% for most adults
- <6.5% if low hypoglycemia risk
- <8% if limited life expectancy, complications
07Outcome At A1c Goal
Continue current regimen, monitor q3-6 months
08Action Intensify Therapy
Add additional agent
- Add GLP-1 RA if not on one
- Add SGLT2i if not on one
- Consider tirzepatide (dual agonist)
- Add basal insulin if A1c still high
09Action Basal Insulin Indication
When oral/injectable agents insufficient
- A1c >10% or glucose >300 at diagnosis
- Symptomatic hyperglycemia
- Catabolic features
- Start 10 units or 0.1-0.2 U/kg/day
- Titrate by 2 units q3 days to FBG goal
- Path rejoins step 06Shared downstream outcome
10Warning Minimize Hypoglycemia Risk
Avoid sulfonylureas as first intensification
- SU: weight gain + hypoglycemia risk
- Prefer GLP-1 RA or SGLT2i instead
- If cost barrier: metformin + SU acceptable
11Decision No ASCVD/HF/CKD
A1c and weight considerations
- If A1c <1.5% above target: monotherapy
- If A1c ≥1.5% above target: consider dual
- Consider weight management goals
12Action Metformin First-Line
Unless contraindicated or not tolerated
- Start 500mg daily with food
- Titrate to 1500-2000mg/day
- Hold if eGFR <30
- Monitor B12 with long-term use
- Path rejoins step 06Shared downstream outcome
13Action Weight Management Priority
If weight loss is primary goal
- GLP-1 RA (high efficacy): semaglutide, tirzepatide
- GIP/GLP-1 RA: tirzepatide
- Or GLP-1 RA + SGLT2i combination
- Path rejoins step 06Shared downstream outcome
Guideline Source
ADA Standards of Care in Diabetes—2025
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address Type 1 diabetes
- Does not cover gestational diabetes
- Drug dosing not included - refer to institutional protocols
- Does not replace shared decision-making with patients
- Insulin titration requires individualized approach
Contraindicated Populations
pediatricpregnancytype1_diabetes
Applicable Regions
USEU
EU: EASD/ADA consensus statement also applicable
US: Based on ADA 2025 Standards of Care
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Type 2 Diabetes Management (ADA 2025)?
The Type 2 Diabetes Management (ADA 2025) is a management clinical algorithm for Internal Medicine. It provides a structured decision tree to guide clinical decision-making, based on ADA Standards of Care in Diabetes—2025.
What guideline is the Type 2 Diabetes Management (ADA 2025) based on?
This algorithm is based on ADA Standards of Care in Diabetes—2025 (DOI: 10.2337/dc25-S009).
What are the limitations of the Type 2 Diabetes Management (ADA 2025)?
Known limitations include: Does not address Type 1 diabetes; Does not cover gestational diabetes; Drug dosing not included - refer to institutional protocols; Does not replace shared decision-making with patients; Insulin titration requires individualized approach. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Type 2 Diabetes Management (ADA 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free